Raising a debut fund in 2026 is hard. Raising one for biotech, a sector investors have spent four years avoiding, is harder still. NeoSci Ventures (NSV) says it has done it anyway. The Singapore-, Taiwan- and US-based venture builder has announced a first close of SGD70 million (US$53 million) for its inaugural institutional fund. The […] The post Taiwan and Singapore back NSV’s US$53M bet on Asia’s biotech pipeline appeared first on e27.
Read full articleSolar scheme promises savings, but at what cost?
Cabinet to weigh B78.5bn development plan for Isan
Amnesty clause may aid Thaksin's bid for B46bn
Ministry widens crackdown on industrial waste
PP urges govt to promote domestic gaming industry
Suvarnabhumi set to double passenger capacity